Targeting enzyme inhibitors in drug discovery.
Drugs that function as enzyme inhibitors constitute a significant portion of the orally bioavailable therapeutic agents that are in clinical use today. Likewise, much of drug discovery and development efforts at present are focused on identifying and optimizing drug candidates that act through inhibition of specific enzyme targets. The attractiveness of enzymes as targets for drug discovery stems from the high levels of disease association (target validation) and druggability (target tractability) that typically characterize this class of proteins. In this expert opinion the authors describe the existing practices and future directions in drug discovery enzymology, with emphasis on how a detailed understanding of the catalytic mechanism of specific targets can be used to identify and optimize small-molecule compounds that interact with conformationally distinct forms of the enzyme, thus resulting in high potency, high selectivity inhibitors.
Copeland
Robert A
RA
Department of Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline, Collegeville, PA 19426, USA. Robert.A.Copeland@gsk.com
Harpel
Mark R
MR
Tummino
Peter J
PJ
D000818:Animals; D001665:Binding Sites; D002384:Catalysis; D015195:Drug Design; D004791:Enzyme Inhibitors; D006801:Humans
D004791:Enzyme Inhibitors